®Based on the topline results from the EPCORE DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps ® NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B ...

三生制药将一款处于临床阶段的双特异性抗体药物以60.5亿美元的价格授权给辉瑞；恒瑞医药与葛兰素 史克（GSK）达成潜在价值125亿美元的交易；信达生物与武田制药就三款产品达成114亿美元的交 易……当下，中国生物医药行业的交易纪录正被本土创新力量持续刷新。 这也印证着，跨国药企在华的研发战略正经历一场悄然却深刻的转型：跨国药企不再仅仅满足于成为成 熟产品的商业化落地者，而是将触角延伸至更早期的本土生物科技创新源头，通过开放创新模式、设立 专项奖项、联合本土孵化器等多种方式，深度融入中国的生物技术（Biotech）生态系统。 近日，艾伯维和荣昌生物宣布签署独家授权许可协议，共同开发、生产以及商业化RC148。根据协议， 艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。荣昌生物将获得6.5亿美元 的首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地 区净销售额的两位数分级特许权使用费。 对艾伯维而言，RC148补充了其在免疫肿瘤学领域的产品组合，尤其是在PD-1/VEGF双抗这一新兴方 向，有望与现有抗体偶联药物（ADC）、肿瘤免疫治疗（IO）药物形 ...

Core Insights - The 44th J.P. Morgan Healthcare Conference has highlighted significant industry developments, including a $1 billion investment by NVIDIA and Eli Lilly to establish a joint research lab in the San Francisco Bay Area to accelerate AI applications in the pharmaceutical sector [1] - The conference serves as a critical platform for domestic pharmaceutical companies to showcase core molecular product capabilities and advance overseas business development collaborations, indicating a return to global value validation for products [2] - The participation of over 8,000 global attendees and more than 500 listed companies underscores the strengthening global competitiveness of Chinese companies in the pharmaceutical sector [2] Group 1: Innovative Drugs - BeiGene focuses on oncology drug development and global commercialization, presenting progress on core products like CDK4 at the conference [2] - Rongchang Biologics has entered an exclusive licensing agreement with AbbVie for the novel PD-1/VEGF bispecific antibody drug RC148, granting AbbVie rights outside Greater China for development, production, and commercialization [2] - Hengrui Medicine, involved in the R&D, production, and sales of innovative and generic drugs, reported that over 50% of its revenue now comes from innovative drugs, with multiple self-developed products receiving approvals [2] Group 2: CRO/CMO - WuXi AppTec provides integrated CXO services covering the entire drug development and manufacturing process, projecting a 32.56% year-on-year growth in net profit for 2025 [3] - WuXi Biologics, specializing in biopharmaceutical CRDMO services, announced 209 new projects, bringing the total to 945, with potential milestone payments exceeding $4 billion from new research contracts [3] - Tigermed offers clinical trial CRO services and participated in the Asia-Pacific session of the conference, providing outsourcing services related to clinical trials for global pharmaceutical companies [3] Group 3: AI in Healthcare - NVIDIA and Eli Lilly's collaboration aims to build AI models to enhance new drug development, with a planned investment of $1 billion over the next five years [4] - RunDa Medical focuses on comprehensive medical testing services and is developing an automated testing interpretation system based on large models [4] - Anbiping has launched a digital pathology AI system and is exploring the registration and commercialization of AI medical devices in cervical cytology [4]

Question-and-Answer SessionI thought just to kick off the conversation, Scott. As we enter 2026, can you just run through top priorities for AbbVie and how you're thinking about the business?Scott ReentsExecutive VP & CFO Sure. Great. Thanks for having us, Chris. We're very excited to be here today and to talk about AbbVie. So when we look at 2026, I would say it's really a continuation of the strategy that we've been articulating. One is just to operate and execute operationally in a way that delivers stro ...

AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra. ...

AbbVie (NYSE:ABBV) FY Conference January 14, 2026 11:15 AM ET Company ParticipantsJeff Stewart - Chief Commercial OfficerScott Reents - CFORoopal Thakkar - EVPConference Call ParticipantsChris Schott - AnalystChris SchottGood morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this Fireside Chat today with AbbVie. From the company, we have Scott Reents, CFO, Jeff Stewart, Chief Commercial Officer, and Roopal Thakkar, Chief Medical Officer. So, happy New Year, guys, and thank ...

Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Good morning from San Francis ...

Core Insights - The collaboration between AbbVie and Rongchang Biopharma marks a significant shift in the global oncology treatment landscape, highlighting the trend of "Chinese innovation + global market" in drug development [1][2] Group 1: Collaboration Details - AbbVie and Rongchang Biopharma signed an exclusive licensing agreement for the development, production, and commercialization of RC148, a bispecific antibody targeting PD-1 and VEGF [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2] Group 2: Market Implications - The deal allows Rongchang Biopharma to accelerate clinical trials for RC148 in China and globally, while also supporting the development of other pipelines [2] - AbbVie aims to enhance its product portfolio in immuno-oncology, particularly in the emerging PD-1/VEGF bispecific antibody space, which could improve its competitiveness in solid tumor treatments [2] Group 3: Industry Trends - The PD-1/VEGF bispecific antibody represents a new class of cancer therapies that may overcome tumor resistance mechanisms by simultaneously blocking PD-1 and VEGF [3][5] - Chinese companies are leading in this field, with significant advancements and approvals, such as the launch of Ak112/Ivonescimab by Kangfang Biopharma, which is the first bispecific antibody combining tumor immunity and anti-angiogenesis mechanisms [3] Group 4: Broader Market Dynamics - The global interest in PD-1/VEGF bispecific antibodies is rising, with several Chinese firms successfully engaging in business development (BD) transactions, reflecting the increasing recognition of Chinese innovative drug assets by multinational pharmaceutical companies [6][7] - In 2025, the total value of Chinese innovative drug licensing transactions exceeded $130 billion, accounting for 49% of the global total, indicating a significant shift in the global pharmaceutical landscape [7][8] Group 5: Future Outlook - The increasing number of approved innovative drugs in China, along with the growing bargaining power of Chinese companies in licensing agreements, suggests a transition from a "follow" to a "lead" position in global pharmaceutical innovation [8][10] - The ability of Chinese companies to negotiate favorable terms in BD transactions is becoming crucial, emphasizing the importance of pipeline strength, data quality, and structured deal design [9][10]

肿瘤双抗治疗的战场再次传来重磅消息，一家中国创新药企与跨国巨头的牵手，不仅是单个药物的授权，更是全球肿瘤治疗格局加速演变的信 号。 1月12日，艾伯维（纽约证券交易所代码：ABBV）和荣昌生物宣布签署独家授权许可协议，共同开发、生产以及商业化RC148。RC148是一种 靶向程序性细胞死亡蛋白1（PD-1）和血管内皮生长因子（VEGF）的新型在研双特异性抗体，目前正由荣昌生物作为单药治疗及联合疗法， 针对多种晚期实体肿瘤进行开发。 根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。荣昌生物将获得6.5亿美元的首付款，并有资格获得最 高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数分级特许权使用费。 有券商医药行业分析师对21世纪经济报道记者表示，从交易结构看，这是一次典型的"中国创新+全球市场"模式，荣昌生物通过RC148的海外 权益转让，不仅锁定了6.5亿美元首付款的现金流，还获得了最高可达49.5亿美元的里程碑收入，以及大中华区以外的销售分成。这笔交易对荣 昌生物的意义在于，充裕的资金可加速RC148在中国及全球的临床试验推进，并支持其 ...

Key Takeaways ABBV agreed to lower U.S. drug prices to match comparable developed markets under MFN terms.Under the pact, ABBV commits $100B over the next decade to boost U.S. R&D and manufacturing capacity.ABBV licensed RemeGen's PD-1xVEGF bispecific RC148 for up to $5.6B to expand its solid tumor pipeline.AbbVie (ABBV) announced that it has signed an agreement with the Trump administration to lower drug prices in the United States.Under the agreement, AbbVie has agreed to reduce the prices of its prescrip ...